openPR Logo
Press release

The Life Raft Group, a Non-profit Supporting Patients with GIST Cancer, Announces Members of the 2021 Medical Advisory Board

03-16-2021 04:54 PM CET | Associations & Organizations

Press release from: The Life Raft Group

The Life Raft Group, a Non-profit Supporting Patients with GIST

Wayne, NJ, March 17, 2021- The Life Raft Group (LRG), a patient advocacy organization supporting patients with Gastrointestinal Stromal Tumor (GIST), a rare cancer, announced today the members of their 2021 Medical Advisory Board.

Comprised of experts from leading academic and medical institutions around the world, the goal of the MAB is to share scientific and research expertise to provide strategic direction on LRG initiatives to ensure the survival and well-being of GIST patients.

The recognized experts and key opinion leaders are:

Suzanne George, MD is the Clinical Research Director of the Center for Sarcoma and Bone Oncology at Dana-Farber Cancer Institute and Associate Professor of Medicine at Harvard Medical School. She also serves as senior physician to the affiliate staff in the Division of Adult Oncology at Brigham and Women’s Hospital.

Michael Heinrich, MD is a medical oncologist and Professor of Medicine and Cell/Developmental Biology at Oregon Health and Science University (OHSU School of Medicine).

Sameer Rastogi, MD is a faculty member in the Department of Medical Oncology at All India institute of Medical Sciences (AIIMS), New Delhi, a leading tertiary care center in North India.

Peter Reichardt, MD is Assistant Professor and Head of the Department of Oncology and Palliative Care at the Helios Klinikum Berlin-Buch in Berlin, Germany, and is Director of the Cancer Center Berlin-Buch and the Sarcoma Center Berlin-Brandenburg.

Gary K. Schwartz, MD is a board-certified medical oncologist and internist and chief of Columbia University Medical Center's Division of Hematology and Oncology.

Jason Sicklick, MD, FACS is an NIH and FDA R01 funded investigator, Professor of Surgery, Executive Vice Chair of Research in the Department of Surgery, and Co-Leader of the Sarcoma Disease Team at the UC San Diego Moores Cancer Center.

Jonathan Trent., MD, PhD the Associate Director for Clinical Research, the Director of the Bone and Soft-tissue Sarcoma Group and Medical Director of the Precision Medicine Initiative at the Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine.

To quote Norman Scherzer, Executive Director of the Life Raft Group, ““The Life Raft Group is excited to collaborate with our Medical Advisory Board to address the vital issues affecting the survival and well-being of GIST patients.”

Contact:
Mary Garland, Director of Communications
mgarland@liferaftgroup.org
155 US Highway 46
Suite 202
Wayne, NJ 07470
(973) 837-9092, ext. 108

About the Life Raft Group

The Life Raft Group is a non-profit with a simple focus: to cure a form of cancer – GIST (gastrointestinal stromal tumors) – and to help those living with it until then. The mission is to ensure the survival of GIST patients through a comprehensive approach connecting individual patients’ needs, the worldwide community of GIST advocates and the global health and research environment. This is achieved by focusing on three key areas: Patient Support & Education, Advocacy and Research.
To learn more, visit www.liferaftgroup.org

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release The Life Raft Group, a Non-profit Supporting Patients with GIST Cancer, Announces Members of the 2021 Medical Advisory Board here

News-ID: 2257171 • Views: 904

More Releases from The Life Raft Group

The Life Raft Group Announces New Board Members
FOR IMMEDIATE RELEASE The Life Raft Group Announces New Board Members Expanded Board will aid in the development of new initiatives Wayne, NJ, April 26, 2021 The Life Raft Group (LRG), a patient advocacy organization specializing in GIST (Gastrointestinal Stromal Tumor) cancer, welcomed two new members to its Board of Directors, Kay Stolzer and Dr. Monica (mOe) Anderson. Comprised of individuals who are passionately invested in finding a cure for GIST, and to supporting

More Releases for GIST

Chatbot Builder Software Market to See Huge Growth by 2027 | Gist, MobileMonkey, …
Global Chatbot Builder Software Market Report 2021 is latest research study released by HTF MI evaluating the market, highlighting opportunities, risk side analysis, and leveraged with strategic and tactical decision-making support. The study provides information on market trends and development, drivers, capacities, technologies, and on the changing investment structure of the Global Chatbot Builder Software Market. Some of the key players profiled in the study are Tars, ChatBot, Gist, MobileMonkey,
YabaLeftOnline NG Presenting the Latest Naija Gist and Nigeria Entertainment New …
YabaLeftOnline NG is a leading online platform in Nigeria that offers a wide variety of news from across the country. The platform displays Naija gist, as well as viral news in Nigeria. On YabaLeftOnline NG, its readers can check out the popular Nigerian music videos, music world’s news, and comedy skits. Whether it is Banky W’s campaign posters being destroyed in Lagos or the latest about BBNaija star Anto, the
Global Gastrointestinal Stromal Tumor Drug Market by Players, Types and Applicat …
"The Report 2018-2025 Gastrointestinal Stromal Tumor (GIST) Drug Report on Global and United States Market,Status and Forecast,by Players,Types and Applications provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz" About Gastrointestinal Stromal Tumor (GIST) Drug Market This report studies the Gastrointestinal Stromal Tumor (GIST) Drug market status and outlook of global and United States, from angles of players, regions, product types and
Asia-Pacific Gastrointestinal Stromal Tumor (GIST) Drug Market Report 2018
In this report, the Asia-Pacific Gastrointestinal Stromal Tumor (GIST) Drug market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. The Values marked with XX is confidential data. To know more about CAGR figures fill in your information so that our business development executive can get in touch with
Asia-Pacific Gastrointestinal Stromal Tumor (GIST) Drug Market Report 2018
In this report, the Asia-Pacific Gastrointestinal Stromal Tumor (GIST) Drug market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. The Values marked with XX is confidential data. To know more about CAGR figures fill in your information so that our business development executive can get in touch with
Gastrointestinal Stromal Tumor (GIST) Pipeline Analysis, 2017 - Clinical Trials …
The gastrointestinal stromal tumor (GIST) pipeline will rise with various collaborations and R&D investments. Hereditary risk and genetic factors play an important role in the development of gastrointestinal stromal tumor. Increasing family history of the disease and genetic factors associated with gastrointestinal stromal tumor and low penetration in the market are contributing towards the development of the pipeline. Additionally, increasing awareness regarding various health issues among people is another major